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Summary
Several cohort studies have investigated the molecular basis of von Willebrand disease (VWD); 
however these have mostly focused on European and North American populations. This study 
aimed to investigate mutation spectrum in 26 index cases (IC) from Turkey diagnosed with all 
three VWD types, the majority (73%) with parents who were knowingly related. IC were screened 
for mutations using multiplex ligation-dependent probe amplification and analysis of all von 
Willebrand factor gene (VWF) exons and exon/intron boundaries. Selected missense mutations 
were expressed in vitro. Candidate VWF mutations were identified in 25 of 26 IC and included 
propeptide missense mutations in four IC (two resulting in type 1 and two in recessive 2A), all 
influencing VWF expression in vitro. Four missense mutations, a nonsense mutation and a small 
in-frame insertion resulting in type 2A were also identified. Of 15 type 3 VWD IC, 13 were 
homozygous and two compound heterozygous for 14 candidate mutations predicted to result in 
lack of expression and two propeptide missense changes. Identification of intronic breakpoints of 
an exon 17–18 deletion suggested that the mutation resulted from non-homologous end joining. 
This study provides further insight into the pathogenesis of VWD in a population with a high 
degree of consanguineous partnerships.
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Introduction
von Willebrand disease (VWD) is a common autosomally inherited bleeding disorder 
resulting from mutations in the von Willebrand factor (VWF) gene. VWD is divided into 
three distinct types; types 1 and 3 result from mild-moderate and severe reductions in 
circulating plasma VWF respectively while type 2 results from specific functional defects 
influencing VWF (1). Type 2 VWD is further subdivided into types 2A, 2B, 2M and 2N 
based on the nature of the particular functional defect (1). Population studies have estimated 
the prevalence of VWD to be between 1% and 1 in 10,000 (2, 3), with the majority of 
reported cases being diagnosed with type 1 (4). Studies performed during the past two 
decades have investigated the molecular basis of VWD in several populations to ascertain 
the mechanisms involved in the pathogenesis of this disorder and to understand how these 
mechanisms differ between VWD types. The majority of these studies have focused on 
European and North American populations where type 1 VWD cases predominate in the 
clinical population. However, studies of ethnic populations with a greater degree of 
consanguineous marriage suggest that recessively inherited forms of VWD are more 
prevalent (5, 6).
The aim of this study was to investigate and characterise VWD pathogenesis in a cohort of 
patients from Turkey. Given the high levels of consanguineous marriage reported (7, 8), it 
was hypothesised that recessively inherited forms of VWD would be more prevalent in this 
cohort and that their investigation would therefore provide additional insight into the 
mechanisms associated with these forms of VWD.
Materials and methods
Study population and phenotypic analysis
Following informed consent, peripheral venous blood samples and plasma were obtained in 
Turkey from 26 families diagnosed with VWD. The majority of index cases (IC; 73%) had 
parents who were either 1st cousins (n=14), 1st cousins once removed (n=1) or 2nd cousins 
(n=4). Only 7 IC had parents who were not knowingly related (#5, 11, 12, 17, 21, 25 and 
26). Skin bleeding times (BT) were determined using a Simplate-II device (General 
Diagnostics, Morris Plains, NJ, USA). Blood samples and plasma were sent to Aarhus, 
Denmark for basic phenotypic and multimer analysis and to Sheffield, UK for genotyping 
and mutation detection. VWF plasma levels (VWF:Ag), ristocetin cofactor activity 
(VWF:RCo) and factor VIII coagulant activity (FVIII:C) were measured as previously 
described (9). Ristocetin induced platelet aggregation (RIPA) was performed on platelet-rich 
plasma using standard methods with a final ristocetin concentration of 1.2 mg/mL (10). 
Plasma multimers were analysed via electrophoresis on 2% or 3% (w/v) sodium dodecyl 
sulphate (SDS)-agarose gels and colorimetric staining (11). Four additional families from 
the cohort were omitted from the study due either to lack of DNA (n=2) or to insufficient 
phenotypic information (n=2).
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Genotyping and mutation analysis
DNA was extracted from citrated blood using standard methods for all 26 IC, available 
family members (n=102) and 100 Caucasian healthy control individuals (HC). Genotypes 
were determined for ABO blood group and two (ATCT)n short tandem repeats (STR) in 
intron 40 (12, 13) in all 26 families as previously described (14). In addition, single 
nucleotide polymorphism (SNP) genotypes were determined via direct DNA sequence 
analysis where relevant. Initially, mutation analysis of the VWF promoter and all 52 exons/
flanking intronic sequence was performed in IC using chemical cleavage mismatch analysis 
(CCMA) or conformation-sensitive gel electrophoresis (CSGE) (9). Standard PCR 
amplification using redesigned primers (sequences and reaction conditions available on 
request) followed by direct DNA sequence analysis of each amplicon was subsequently 
performed to confirm mutations identified and to identify additional mutations not detected 
using CCMA or CSGE.
Multiplex ligation-dependent probe amplification (MLPA)
MLPA, a technique based on sequence-specific probe hybridisation to genomic DNA (15), 
was used to screen IC and 5 HC for copy number variation (CNV) in VWF, utilising VWF-
specific kits (P011-A1/P012-A1 and P011-B1/P012-B1; MRC-Holland b.v., Amsterdam, 
The Netherlands). Fragment size analysis was performed using an ABI 3730 DNA 
sequencer and Peak Scanner™ software v1.0 (Applied Biosystems Europe BV, Warrington, 
UK). Calculation of copy number ratios for each exon-specific amplicon was performed in 
comparison with HC using the gene dosage analysis method developed by the National 
Genetics Reference Laboratory (Manchester, UK; http://www.ngrl.org.uk/Manchester/
publications/MLPA%20Spreadsheets).
Characterisation of the exon 17–18 deletion
The size of the exon 17–18 deletion was estimated using Southern blot analysis utilising 
standard procedures. Briefly, 10 μg DNA digested overnight with EcoRI was 
electrophoresed on a 0.8% (w/v) agarose gel for 18 h, blotted on Hybond-N nylon 
membrane (Amersham Pharmacia Biotech UK Ltd., Bucks) and VWF specific bands 
detected using a full length VWF cDNA probe labelled with 32P α-dCTP (Amersham). 
Long-range PCR (primer sequences and reaction conditions available on request) utilising 
the Expand Long Template PCR System (Roche Diagnostics Ltd., Burgess Hill, UK) 
followed by direct DNA sequence analysis was used to determine breakpoints. Multiplex 
PCR was designed to detect the exon 17–18 deletion utilising standard Taq polymerase 
(deletion-specific forward primer: 5′-GGAAGTTGGGATGAGGTTCA-3′; wild-type 
forward primer: 5′-GTATCTGCTCCTGCCATCGT-3′; reverse primer: 5′-
ATTCCCTGCAGCATCTCTGT-3′).
Expression of recombinant VWF containing p.S49R or p.R324Q
The expression vector containing wild-type full length VWF cDNA (pSVH vWF1; WT) was 
obtained as described (9). The expression vector containing c.147C>A (pVWF-S49R) was 
constructed via mutagenesis of shuttle vector pXbaI, which contained ~450 bp of WT 
(encompassing exons 2–4) obtained by XbaI digestion cloned into pGEM-3Z (Promega UK 
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Ltd., Southampton, UK). The expression vector containing c.971G>A (pVWF-R324Q) was 
constructed via mutagenesis of shuttle vector pKpnI, which contained ~4.5 kb of WT 
(encompassing exons 4–28) obtained by KpnI digestion cloned into pGEM-3Z. Site-directed 
mutagenesis of pXbaI and pKpnI was performed using the GeneEditor™ system (Promega) 
and mutagenic oligonucleotides 5′-TTGATGGGAGAATGTACAGCT-3′ (c.137_157 of 
VWF; pXbaI) and 5′-GTCAGGAGCAATGCGTGGATG-3′ (c.962_982 of VWF; pKpnI). 
Mutant fragments were sub-cloned back into WT VWF cDNA and sequence analysis 
confirmed the presence of each mutation in the p.VWF-S49R and p.VWF-R324Q vectors.
Expression of WT, p.VWF-S49R and p.VWF-R324Q in COS-7 cells, steady-state analysis 
of VWF secretion and multimer analysis of secreted VWF concentrated from COS-7 growth 
medium following transfection with WT or p.VWF-S49R was performed as described (9). 
Multimer analysis of secreted VWF concentrated from COS-7 growth medium following 
transfection with WT and/or pVWF-R324Q was performed in Hamburg, Germany via 
electrophoresis on medium resolution (1.5% w/v) SDS-agarose (16).
In silico analysis
The effect of candidate missense mutations on VWF was predicted using three online 
protein prediction tools: Align-Grantham Variation Grantham Deviation (A-GVGD) (17), 
PolyPhen-2 (18) and Sorting Intolerant From Tolerant (SIFT) (19). The effect of candidate 
splice mutations was predicted using six online prediction tools (20). Multi-species protein 
alignment was performed using ClustalW2 (21). All in silico analysis was performed in June 
2011. Sequence numbering followed Human Genome Variation Society nomenclature with 
‘A’ of the first methionine termed nucleotide 1 (nucleotide RefSeq NM_000552.3; amino 
acid RefSeq NP_000543.2).
Results
Families from all regions of Turkey were referred to the Pediatric Hematology Unit, Ankara 
for diagnosis. Bleeding history in the IC, family history of bleeding, bleeding time (BT), 
VWF:Ag, VWF:RCo and FVIII:C levels were taken into account when diagnosing VWD. 
BT comprised part of the initial diagnosis of patients with IC considered to have VWD if BT 
was ≥6 min. IC were initially diagnosed with type 1 VWD (n=5), type 2 VWD (n=6) and 
type 3 VWD (n=15), but final diagnosis was altered in five IC following detailed phenotypic 
and mutation analysis (Table 1). Mutation analysis identified 24 different mutations in 25/26 
(96%) of IC, each of which segregated with disease phenotype (Table 1).
Type 1 VWD
Mutations were identified in all five IC initially diagnosed with type 1 VWD. Four of the 
mutations resulted in missense alterations within the VWF propeptide; p.S49R, p.R273W 
and p.R324Q. The p.R273W mutation was recessively inherited in two IC, both of whom 
had a severe type 1 phenotype (VWF:Ag 6 and 9 IU/dL, VWF:RCo 6 and 4 IU/dL 
respectively). The other two mutations were dominantly inherited and associated with a mild 
type 1 phenotype. The remaining IC was heterozygous for a p.Y1456* nonsense mutation.
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Previous functional analyses investigating the influence of the p.R273W mutation on VWF 
storage and secretion have confirmed that it causes severe intracellular retention of VWF in 
vitro (14, 22, 23), however the other two propeptide mutations had not been previously 
characterised. Both mutations were shown to affect poorly conserved VWF residues (Fig. 
S1) and in silico analysis predicted that both mutations would be benign. In vitro 
characterisation of recombinant VWF containing each mutation highlighted that both 
mutations had a significant influence on VWF expression (Fig. 1). Expression of p.S49R 
resulted in a significant increase in the amount of VWF secreted from the cell compared to 
WT (100%) both when expressed in homozygous form (139%) and heterozygous form 
(109%; Fig. 1). Conversely, expression of p.R324Q caused a significant retention of VWF 
within the cell compared to WT (100%) when expressed in homozygous (113%) and 
heterozygous (106%) forms (Fig. 1). Neither IC had abnormal multimers (Table 1; Fig. 1); 
however when p.S49R was expressed alone in vitro, a reduction in high molecular weight 
multimers was observed. Multimer profiles following in vitro expression of p.R324Q were 
normal (Fig. 1).
Type 2 VWD
IC diagnosed with type 2 VWD were initially classified as having either 2A or 2N VWD. 
The two IC with type 2N were homozygous for missense mutations located in the D′ 
(p.C788R) and D3 (p.C1225G) domains respectively. When compared against normal 
plasma (100%), patient plasma had reduced FVIII binding capacity (VWF:FVIIIB) similar 
to that observed in plasma from a known type 2N patient homozygous for p.T791M 
(p.C788R homozygote 0% (heterozygote 49%) vs. 1.3%; p.C1225G homozygote 7.1% vs. 
7.1%) (9, 24). Previous investigations have also shown that these mutations impair VWF 
secretion and FVIII binding in vitro, confirming that both account for the observed disease 
phenotype (9, 23). Mutations were identified in three of the four IC with type 2A VWD. 
Each had a classic dominantly inherited 2A phenotype. One IC had the common p.R1597W 
missense mutation located in the VWF A2 domain (25). The other two IC had novel 
mutations; a p.L1657H missense mutation in the A2 domain and a small 9 bp duplication 
resulting in a three amino acid insertion in the A1 domain (p.Y1271_C1272insYFY) 
respectively. A p.L1657I mutation has been previously described in type 2A VWD (26) and 
substitution of p.C1272 has been reported several times in type 2A (25).
Despite performing MLPA and sequence analysis of all 52 exons and closely flanking 
intronic sequence, no mutation was identified in the remaining IC diagnosed with type 2A 
VWD. Notably, STR/SNP genotyping of the IC and their parents was consistent with an 
autosomal recessive inheritance pattern (data not shown) and the multimer profile observed 
in the IC correlated well with multimer patterns reported in type 2A(IIC) patients (Fig. 2) 
(27).
Type 3 VWD
Mutations were identified on both alleles in all IC diagnosed with type 3 VWD, the majority 
of whom were homozygous for a single point mutation (13/15; 87%). Most candidate 
mutations (n=16) were predicted to result in null alleles and included nonsense (n=6), 
frameshift (n=4) and splice mutations (n=3) plus a deletion of exons 17–18, whilst two were 
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missense mutations. Only four of these mutations had been reported previously (Table 1) 
(25, 28–30).
In silico analysis of the three candidate splice mutations predicted that they would result in 
exon skipping (n=2) or intron retention (n=1) resulting in a frameshift (Table 1). A 
homozygous deletion of exons 17–18 was identified during PCR analysis of VWF in IC #3 
through lack of amplification of these exons. Southern blot analysis of genomic DNA 
highlighted a novel ~8 kb band (Fig. 3A) indicating that the deletion encompassed the 
EcoRI restriction enzyme site within intron 18 and at least part of intron 16. MLPA analysis 
confirmed the deletion was recessively inherited (Fig. 3B) and long-range PCR followed by 
direct DNA sequencing mapped the breakpoints (c.2186+2253_2442+3683del, predicted to 
result in p.C729Wfs*29) and indicated that the deletion was 9683 bp in size (Fig. 3C).
Two type 3 VWD IC were homozygous for missense mutations in the VWF propeptide. One 
IC had the p.R273W mutation which has been characterised and shown to result in 
intracellular retention (14, 22, 23). The remaining IC had a novel p.R34G mutation. p.R34 is 
completely conserved across species (Fig. S1) and in silico evolutionary conservation 
analysis predicted that the mutation would have a detrimental effect on the VWF protein.
Phenotype of heterozygous type 3 VWD parents
Both parents were available for all fifteen type 3 VWD IC. Only three individuals (10%) had 
increased bleeding times (6, 7 and 13 min), but VWF:RCo and VWF:Ag were reduced 
below the normal range in 15 (52%) and 13 (43%) of individuals analysed respectively 
(Table 2). Mean VWF:RCo/VWF:Ag ratio was 1.0 for all individuals analysed. None of 
these 30 heterozygous carriers of 16 different mutations had abnormal multimer profiles 
(Table 2). Fourteen individuals reported one or more bleeding symptoms (47%), but their 
VWF levels were not significantly different to those of 16 individuals who did not report 
symptoms (Table 2). It has previously been observed that heterozygous carriers of type 3 
VWD mutations have significantly raised ratios of FVIII:C to VWF:Ag (31, 32). In this 
cohort, FVIII:C/VWF:Ag ratio (mean 1.4) was increased (1.5–2.3) in 43% of type 3 VWD 
carriers. Notably an increased ratio was not observed in splice mutation carriers (mean 
FVIII:C/VWF:Ag ratio 0.9) with four of four carriers having normal ratios, whereas in 
nonsense/frameshift mutation carriers 11 of 21 (52%) had raised ratios (mean FVIII:C/
VWF:Ag ratio 1.5; Table 2).
Discussion
To date there have been few reports concerning VWD in populations with high rates of 
consanguinity. In this study, a cohort of 26 Turkish IC diagnosed with VWD types 1–3 and 
their family members had phenotypic and genotypic investigation of their VWD to 
understand the mutations responsible and the consequences of those mutations. Prolonged 
BT in all IC may have enhanced the selection of cases with significant bleeding, leading to 
the high detection rate for mutations in this cohort. At the time of recruitment VWF collagen 
binding (VWF:CB) assays were not routinely performed, so unfortunately VWF:CB data 
(which might have allowed additional characterisation of VWD phenotype) was unavailable 
for this cohort.
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Four of the five type 1 VWD mutations were missense and all occurred in the VWF 
propeptide. p.R273W has previously been shown to result in intracellular retention (14, 22, 
23), and in vitro characterisation carried out in this study suggests that both the p.S49R and 
p.R324Q mutations also affect VWF expression. In addition to the three missense mutations 
reported here, 36 missense mutations have been reported within the VWF propeptide to date 
(25, 33). Six of these (p.D141Y, p.G160W, p.N166I, p.C275R/S and p.R760C) have also 
been shown to affect VWF expression in vitro when expressed in the heterozygous form (25, 
33). In comparison to these mutations and p.R273W, the effect of p.S49R and p.R324Q on 
VWF expression is not as pronounced. However, all these previously reported mutations 
affect VWF residues completely conserved across species, unlike p.S49R and p.R324Q, 
suggesting that disruption of p.S49 and p.R324 residues is likely to be less detrimental.
In vitro expression of recombinant p.S49R showed a significant increase in VWF secreted 
from the cell compared with WT both when expressed in the homozygous form or when co-
expressed in the heterozygous form with WT, although in both cases there was no 
significant difference in VWF retained within the cell (Fig. 1). The IC had a normal 
multimer profile, however homozygous expression of recombinant p.S49R appeared to 
indicate a loss of high molecular weight multimers (multimer analysis of recombinant 
p.S49R/WT was not performed). p.S49R may therefore interfere with the VWF 
multimerisation process within the cell resulting in only low molecular weight forms of 
VWF being secreted. Increased secretion of VWF has not been previously reported, 
however mutations affecting amino acid substitutions in proximity to p.S49 have not been 
functionally characterised (25, 33). Although VWF:Ag level in the IC (58 IU/dL) was within 
the normal range observed in this study (46–146 IU/dL), the IC suffered from frequent 
epistaxis and prolonged bleeding from superficial wounds. The IC also had blood group O 
and combined with p.S49R this may be sufficient to explain the mild bleeding phenotype 
observed. In addition, p.S49R was not present when screened in 35 HC and 35 unrelated 
Turkish family members, and has not been reported by HapMap (34), the 1000 Genomes 
Project (35) or in African-American HC (36), which suggests that this variant is unlikely to 
be a polymorphism.
Expression of recombinant p.R324Q resulted in a significantly reduced VWF secretion and 
increased intracellular retention of VWF both when expressed in homozygous or 
heterozygous forms, although recombinant p.R324Q still formed normal multimers (Fig. 1). 
p.R324Q is therefore likely to result in type 1 VWD through impaired secretion of VWF, 
similar to several other type 1 VWD mutations (37).
Interestingly, in this cohort, p.R273W was initially associated with both recessive type 1 and 
type 3 VWD. Of note, a recessive type 2A VWD patient, compound heterozygous for 
missense mutations p.C275R and p.P1337L, has been described with a similar phenotype to 
both IC initially diagnosed as recessive type 1 (VWF:Ag 7 IU/dL, VWF:RCo 2 IU/dL, 
FVIII:C 32 IU/dL, BT 11 min, absent high molecular weight multimers); the p.C275R 
mutation resulting in intracellular retention of VWF and contributing to the abnormal 
multimer profile (38). These two IC may therefore be more accurately classified as having 
recessive 2A VWD (despite IC #2 having a VWF:RCo/VWF:Ag ratio of 1.0 as the ratio 
may be misleading when VWF:RCo is <10 IU/dL) and re-examination of the multimer 
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profile in one of these IC supported a reclassification. The difference in phenotype between 
the three p.R273W IC cannot be explained by ABO blood group, as both the type 3 and one 
of the type 2A IC had blood group A (14). Heterozygous carriers of this mutation did not 
report a bleeding phenotype (Table 2). It is possible that this phenotypic difference between 
IC is due to other genetic influences, for example polymorphic variation within the VWF 
locus or other genes (39, 40). However, DNA sequence analysis of VWF did not reveal 
differences between VWF haplotypes in the IC (14).
One IC (initially classified as type 1) was heterozygous for a p.Y1456* nonsense mutation 
and had a severe phenotype (VWF:Ag 15 IU/dL, VWF:RCo <3 IU/dL, BT >20 min, 
abnormal multimers). This nonsense mutation has previously been reported in a compound 
heterozygous type 3 VWD patient and the familial carrier of this mutation had normal VWF 
levels and no bleeding symptoms (41). A further unidentified mutation in addition to this 
nonsense mutation must occur in this IC to explain the severe phenotype observed and this 
IC could also be more accurately classified as having recessive 2A VWD. No other mutation 
was identified and no further DNA is available for this IC. Linkage analysis indicated that 
the IC inherited the mutation from their father, from whom no DNA or phenotypic data was 
collected.
Two IC were homozygous for novel missense mutations (p.C788R and p.C1225G 
respectively) and initially diagnosed with type 2N VWD based on impaired VWF:FVIIIB 
results (9), despite both IC having FVIII:C levels similar or higher than those recorded for 
VWF:Ag and VWF:RCo. Interestingly, one of these mutations (p.C1225G) has recently 
been identified in two German patients classified with type 2A VWD because the mutation 
had no detectable effect on VWF:FVIIIB (42). As mentioned by Yadegari and colleagues 
(42), it seems likely that p.C1225G may belong to a group of mutations that have pleiotropic 
effects on VWF function, and p.C788R may also fall into this category.
This study failed to identify a mutation in IC #4 who had an apparent recessive type 2A(IIC) 
VWD phenotype and in whom pedigree analysis indicated homozygous inheritance. 
Although rare, several 2A(IIC) mutations have been reported clustered within the D2 
domain encoded by exons 11–17 (25, 43) and the phenotype in the IC resembles those 
previously reported. Despite analysis of DNA from the IC using both MLPA and direct 
DNA sequencing, no evidence of CNV or any mutation in exons 1–52 was identified. The 
possibility that the IC had a homozygous deep intronic mutation within this region affecting 
mRNA splicing cannot be dismissed (44). To result in a 2A(IIC) phenotype, a candidate 
mutation would have to result in the production of an in-frame altered VWF protein 
disrupting VWF multimerisation. An intronic mutation leading to creation of a cryptic splice 
site and introduction of an additional in-frame exon is a possible explanation, similar to 
recently reported F8 intronic mutations causing mild haemophilia A (45). Unfortunately, 
mRNA from the IC was unavailable and further analysis would therefore need to focus on 
analysis of genomic DNA for variation in introns 10–17, which range in size from ~750 bp 
up to 6 kb. DNA sequence analysis of those introns ≤1.2 kb in size (i.e. introns 11, 12 and 
14) revealed no candidate mutation in the IC.
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The majority of IC had type 3 VWD. In total, 16 different mutations were found in this 
group, 87% predicted to result in a null allele (6 nonsense, 5 frameshift and 3 splice), 
comparable with other type 3 studies (43). A homozygous p.P2063S missense change was 
initially identified in IC #9. Although p.P2063S has a reported population frequency of 2.5% 
(46) and was previously considered to be a mutation (25), it does not influence VWF 
expression and is now considered to be a polymorphism (37). Recent DNA sequence 
analysis identified a homozygous p.Q1734* nonsense mutation in IC #9 (Table 1), providing 
further indication that p.P2063S is not responsible for the type 3 phenotype. No VWF 
inhibitor history was reported and no de novo mutations were identified in any of the type 3 
VWD IC.
A previously unreported exon 17–18 deletion was mapped to breakpoints within intron 16 
(c.2186+2253) and intron 18 (c.2442+3683) allowing design of a specific multiplex PCR to 
detect this deletion (Fig. 3D). Previously reported large deletions in type 3 VWD have been 
shown to occur via homologous recombination involving Alu repetitive elements (43), 
however breakpoints for this deletion occurred within a L2b long interspersed nuclear 
element (LINE) and within a MIRb short interspersed nuclear element (SINE) respectively. 
Notably, it has been shown that non-homologous recombination can occur between different 
repetitive elements via a mechanism of non-homologous end-joining due to microhomology 
around the breakpoints (47), most recently in CNV events observed in haemophilia A (48). 
The sequence at the exon 17–18 deletion breakpoints has CC dinucleotide microhomology 
and there are motifs associated with DNA recombination located within 75 bp of each 
breakpoint, i.e. deletion hotspot consensuses, DNA polymerase arrest sites and DNA 
polymerase a/b frameshift hotspots (Fig. 3C) (49, 50). The deletion is therefore proposed to 
have resulted from non-homologous end joining. It leads to introduction of a premature stop 
codon (p.C729Wfs*29) and is likely to result in nonsense mediated decay, and thus a null 
allele.
In conclusion, this study provides further insight into the pathogenesis of VWD. The 
observations of recessive type 2A VWD, including type 2A(IIC), and a high proportion of 
type 3 VWD cases in this study highlights the contribution of consanguinity to VWD and 
provides additional insight into the mechanisms associated with VWD.
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What is known about this topic?
• von Willebrand disease (VWD) is a common autosomally inherited bleeding 
disorder with a population prevalence between 1% and 1 in 10,000.
• In Europe and North America, dominantly inherited forms of VWD, especially 
type 1 VWD, predominate in the clinical population.
• Studies of ethnic populations with a greater degree of consanguineous marriage 
suggest that recessively inherited forms of VWD are more prevalent.
What does this paper add?
• Investigation of a cohort of VWD families demonstrating a high proportion of 
consanguineous marriage identifies a significant proportion of rare VWD forms 
confirming the contribution of consanguinity to VWD severity.
• Eighteen novel VWD mutations were identified in this patient cohort including 
three missense mutations in the von Willebrand factor propeptide and a large 
deletion of exons 17–18.
• Investigation of these novel mutations and rarer forms of VWD provides further 
insight into the pathogenesis of VWD and the associated disease mechanisms.
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Figure 1. 
Recombinant VWF (rVWF) expression in COS-7 cells (mean values from six independent 
experiments). A and B) Mutant rVWF (p.S49R and p.R324Q respectively) secreted into the 
culture medium and retained within the cell relative to WT rVWF only (100%). C and D) 
Comparison of patient multimer profile (electrophoresed on 2% SDS-agarose) and multimer 
profile of secreted rVWF (1.5% SDS-agarose) observed for p.S49R (rVWF in homozygous 
state only) and p.R324Q respectively (IC, index case; F, father; M, mother; NP, normal 
plasma; *p<0.05, two-tailed Student’s t-test).
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Figure 2. 
Multimer profiles observed in IC #4 with 2A(IIC) VWD and their parents (M, mother: 
VWF:Ag 60 IU/dL, VWF:RCo 36 IU/dL, FVIII:C 98 IU/dL, no bleeding symptoms; F, 
father: VWF:Ag 26 IU/dL, VWF:RCo 30 IU/dL, FVIII:C 107 IU/dL, moderate bleeding 
symptoms) when electrophoresed on 2% (A) or 3% (B) SDS-agarose (NP, normal plasma).
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Figure 3. 
Characterisation of the exon 17–18 deletion. A) Southern blot analysis of EcoRI digested 
DNA highlighting the novel ~8 kb fragment (*) observed in IC #3 but neither HC. B) 
Confirmation of the exon 17–18 deletion following dosage analysis by MLPA in the index 
case (IC), a heterozygous parent (P) and a healthy control (HC). C) Deletion breakpoints in 
intron 16 and intron 18 highlighting 2 bp microhomology (dotted border), deletion hotspot 
consensus sequences (solid underline), DNA polymerase arrest sites (lowercase) and DNA 
polymerase a/b frameshift hotspots (dotted underline) close to the breakpoint junctions. D) 
Multiplex PCR designed to detect the exon 17–18 deletion (DSPF, deletion-specific forward 
primer; WTPF, wild-type forward primer; R, reverse primer) further confirming the 
homozygous inheritance in the index case (IC) and heterozygous inheritance in both parents 
(F and M).
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